Nu-Med Plus Develops Proprietary Compressed Tablet for Inhaled Nitric Oxide Delivery System for Hospitals

Nu-Med Plus Inc. (OTCMKTS:NUMD) announced that it has completed the development of a compressed proprietary tablet formulation for their Inhaled Nitric Oxide Hospital System for use in Adults, Pediatrics and Neonates who are on a ventilator in a hospital setting under close medical supervision.

As quoted in the press release:

Nitric oxide is a medically essential gas that is presently used in Neonate Hypoxia therapy (inadequate oxygen level in newborns) and may have future applications for a variety of other diseases and complications that are currently being investigated.

Jeff Robins, president and CEO of Nu-Med Plus, Inc., commented:

We are excited to have completed our Compressed Tablet Technology that allows us to produce Inhaled NO more efficiently from our proprietary formulation, this advancement should contribute to the overall direction of reducing the existing high cost of therapy and making our hospital system an affordable treatment for complications requiring Inhaled NO gas.

Click here to read the full Nu-Med Plus Inc. (OTCMKTS:NUMD) press release.